The Goldman Sachs Group upgraded shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) to a strong-buy rating in a research note issued to investors on Thursday morning, Zacks.com reports.
Merck KGaA Trading Up 3.3 %
Shares of OTCMKTS MKGAF opened at $189.00 on Thursday. Merck KGaA has a 1-year low of $143.46 and a 1-year high of $200.56. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The business’s 50 day moving average is $182.06 and its two-hundred day moving average is $175.32. The stock has a market capitalization of $24.43 billion, a P/E ratio of 27.75 and a beta of 0.96.
Merck KGaA (OTCMKTS:MKGAF – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported $1.51 earnings per share for the quarter. The company had revenue of $5.76 billion for the quarter. Merck KGaA had a return on equity of 10.17% and a net margin of 12.60%. As a group, research analysts expect that Merck KGaA will post 9.5 EPS for the current year.
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Read More
- Five stocks we like better than Merck KGaA
- What is a Bond Market Holiday? How to Invest and Trade
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- P/E Ratio Calculation: How to Assess Stocks
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Insider Buying Explained: What Investors Need to Know
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
